Testing NPI-001 for vision in Usher syndrome
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital clinical trials.
This trial tests a drug called NPI-001 (N-acetylcysteine) to see if it can help protect the light-sensing cells in the eyes of people with Usher syndrome, a genetic condition that causes vision and hearing loss. The study lasts 24 months and measures how well the retina stays healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Usher syndrome.
- You need to have a certain amount of healthy retina (at least 500 microns wide) in the central part of your vision in both eyes.
- You must be able to see at least 20 points on a specialized vision test in at least one eye.
- You should not have other serious eye conditions that blur vision or make it hard to focus.
- Women who can get pregnant and men who can father children must use reliable birth control during the study and for 4 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication (NPI-001) to see if it can preserve the light-sensing cells in the retina for people with retinitis pigmentosa caused by Usher syndrome. It lasts 24 months and requires several eye exams to monitor changes.
This study follows people with Usher syndrome type 1B over time to learn how vision loss progresses. It also tests new ways to measure functional vision, which may help design future treatments.
This study tests a new eye injection containing pitavastatin, a drug normally used for cholesterol, wrapped in tiny particles. The goal is to see if it is safe and if it can help slow vision loss in people with retinitis pigmentosa.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
This trial tests a new gene therapy injection (ZM-02) that uses light-sensitive proteins to help restore vision in people with advanced retinitis pigmentosa. It’s designed to see if the treatment is safe and can improve vision.
This trial tests a gene therapy injection (UGX202) for people with advanced retinitis pigmentosa (RP) who have very poor vision. It aims to see if the treatment can help improve or preserve sight.
Hear when a new Usher Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.